PACLITAXEL

SynDRA canonical compound SYN0000463 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	NR1I2
Mechanism of action	Tubulin inhibitor
Indication	breast cancer \| non-small cell lung cancer (NSCLC) \| ovarian cancer
Disease area	oncology

All known targets

NR1I2
TUBB
ABCB1
TUBB3
TUBB1
TUBB2B
TUBB2A
TUBB4A
TUBB4B
TUBB6
BCL2
TUBB8

Mechanisms of action (all sources)

microtubule inhibitor
tubulin polymerization inhibitor
BCL2 MODULATOR
TUBB INHIBITOR
TUBB1 INHIBITOR
TUBB2A INHIBITOR
TUBB2B INHIBITOR
TUBB3 INHIBITOR
TUBB4A INHIBITOR
TUBB4B INHIBITOR
TUBB6 INHIBITOR
TUBB8 INHIBITOR

Drug classes

Microtubule Inhibitor
Antineoplastic Agents
Antimitotic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators

ATC classes

L01C · PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

Cross-references

PubChem CID: 36314
ChEMBL: CHEMBL428647
DrugBank: DB01229
ChEBI: CHEBI:45863
KEGG: D00491
RxNorm: 56946
PDB: TA1
Wikipedia: Paclitaxel
TTD: D0C4RB
LINCS BRD: BRD-K62008436

Synonyms

Reported adverse events

Anaphylaxis
Arthralgia
Infection
Neutropenia
Thrombocytopenia
Alopecia
Nausea
Hypotension
Myalgia
Asthenia
Hypersensitivity
Radiation pneumonitis

Look up PACLITAXEL in the interactive SynDRA portal →